Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D, Chronic Kidney Disease (CKD) and the Microcirculation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. eGFR between 15 and 60 ml/min/1.73m2~2. Serum 25 (OH) vitamin D levels \<30nmol/L~3. No evidence of diabetes mellitus (fasting blood sugar \<7.1, not taking any diabetic medication)~4. Not receiving haemo or peritoneal dialysis~5. No dialysis therapy within the last 3 months~6. Age \> 18 years and \< 80 years~7. Patient agrees not use any medications (prescribed or over-the-counter including herbal remedies) judged to be clinically significant by the Principal Investigator during the course of the study.~8. Able to understand and sign the written Informed Consent Form.~9. Able and willing to follow the Protocol requirements.~Exclusion Criteria:~1. Currently receiving oral ergocalciferol at any dose~2. Received IM ergocalciferol therapy within last 3 months~3. Receiving renal replacement therapy of any type or having recently received any form of dialysis (within 3 months)~4. Pacemaker or any other implanted cardiac device~5. Serum calcium above 2.6 mmol/L at screening~6. Pregnant or lactating~7. Known hypersensitivity to ergocalciferol~8. Patient known to have a condition which predisposes to hypercalcaemia (multiple myeloma, sarcoidosis, other granulomatous disease)~9. Initial blood pressure of \>160/100 mmHg~10. History of significant liver disease or cirrhosis~11. Anticipated requirement for dialysis in 6 months~12. Malabsorption, severe chronic diarrhea, or ileostomy~13. Known diagnosis of hypervitaminosis D~14. Known to have diabetes mellitus~15. Known to have renal calculi~16. Known to have systemic sclerosis, Raynaud's phenomenon or other disease associated with known microcirculatory dysfunction~17. Concurrent participation in any other research study~18. Unwilling or unable to complete study protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Ergocalciferol (oral) (Type: ACTIVE_COMPARATOR): ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo at same dose schedule as ergocalciferol

Based on this trial design, predict the completion outcome and termination type (if applicable).